Cristina Papayannidis, C.D.B. (2013). Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. BLOOD, 122, 3911-3911.
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience
Cristina Papayannidis;Caterina De Benedittis;Simona Soverini;Ilaria Iacobucci;Maria Chiara Abbenante;Chiara Sartor;Maria Teresa Bochicchio;Anna Ferrari;Claudia Venturi;Valentina Robustelli;Andrea Ghelli Luserna Di Rorà;Viviana Guadagnuolo;Emanuela Ottaviani;Nicoletta Testoni;Carmen Baldazzi;Simona Luatti;Sarah Parisi;Stefania Paolini;Cristina Clissa;Alberto Conficoni;Federica Frabetti;Elisa Lani;Silvia Piccari;Giovanni Martinelli
2013
File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
